COMP vs HELP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COMP and HELP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COMP and HELP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Compass, Inc. is a tech-enabled residential real estate company that operates an owned-brokerage model in the United States. It recruits real estate agents onto a proprietary software platform that handles marketing, client management, and transaction workflow, and it earns revenue primarily as a share of the sales commissions its agents generate when homes change hands. Because agents keep most of each commission under negotiated splits, Compass keeps only a thin slice of a very large revenue number, so its margins are structurally low and its results track the volume of home sales closely. The company has expanded into adjacent services such as title, escrow, and mortgage referrals to capture more of each transaction.

Full COMP guide

Helus Pharma Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and completed its legal name change from Cybin Inc. on October 1, 2026 after shareholders approved it on September 22, is a Toronto-based clinical-stage pharmaceutical company. The ticker did not change, and the shares also trade on Cboe Canada. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog with FDA Breakthrough Therapy Designation that is being studied as an adjunctive treatment for major depressive disorder in a registrational Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.

Full HELP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COMP drivers: Scale and market leadership; Improving profitability.
• HELP drivers: Phase 3 depression readout; Anxiety program optionality.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Compass is highly exposed to the housing cycle: when mortgage rates rise or home sales slow, commission revenue falls quickly while many costs remain, and the stock moves with bond yields (it gained about 6% in a single mid-October session as long-term rates fell). For HELP, as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COMP if you believe its drivers more; HELP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COMP and HELP guides.

COMP. A residential brokerage like Compass reports a very large revenue number, but most of each commission is paid out to agents, so the figures to watch are EBITDA and free cash flow rather than top-line growth alone. The trailing P/E near 156x reflects only a sliver of GAAP profit, while the forward P/E near 11x assumes about $0.84 of EPS, so the valuation depends heavily on whether Anywhere synergies show up. At ~0.7x sales and with 13 analysts carrying a mean target near $14.62, the market is pricing the housing cycle and integration risk more than the scale.

HELP. Standard earnings multiples do not apply because Helus has no revenue and runs at a loss while funding Phase 3 trials. At roughly $784 million, the market value is now well above the ~$166 million cash balance, so investors are assigning a substantial premium to the pipeline ahead of the Q4 2026 Phase 3 data, a bigger bet than earlier in the year. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.

Headline figures (approximate, October 2026): COMP shows revenue (ttm) ~$10.6B (Q2 2026 +109% YoY with Anywhere), net income (ttm) ~$67.5M (~0.6% net margin), margins (ttm) ~14% gross, ~3.8% operating, p/e (trailing / forward) ~156x / ~11x; HELP shows share price ~$10.73 (Oct 16, 2026), market cap ~$784M, revenue (ttm) $0 (pre-revenue), net loss (ttm) ~$171M.

COMP and HELP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COMP and HELP exposure against your real portfolio. It is not an investment adviser.